Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/27973
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | Bittner, V. A. | |
dc.contributor.author | Schwartz, G.G. | |
dc.contributor.author | Bhatt, D.L. | |
dc.contributor.author | Chua, T | |
dc.contributor.author | de Silva, H.A. | |
dc.contributor.author | Diaz, R. | |
dc.contributor.author | Goodman, S.G. | |
dc.contributor.author | Harrington, R.A. | |
dc.contributor.author | Jukema, J.W. | |
dc.contributor.author | McGinniss, J. | |
dc.contributor.author | Pordy, R. | |
dc.contributor.author | Garon, G. | |
dc.contributor.author | Scemama, M. | |
dc.contributor.author | White, H.D. | |
dc.contributor.author | Steg, P.G. | |
dc.contributor.author | Szarek, M. | |
dc.contributor.author | ODYSSEY OUTCOMES Investigators | |
dc.date.accessioned | 2024-08-15T04:01:37Z | |
dc.date.available | 2024-08-15T04:01:37Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | Journal of Clinical Lipidology.2024 [Online ahead of print. 2024 Apr 10] | en_US |
dc.identifier.issn | 1933-2874 (Print) | en |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/27973 | |
dc.description | Indexed in MEDLINE | en |
dc.description.abstract | Background: The ODYSSEY OUTCOMES trial (NCT01663402) compared the effects of the pro- protein convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo on major adverse cardiovas- cular events (MACE) in patients with recent acute coronary syndrome (ACS). Objective: We assessed efficacy and safety of alirocumab versus placebo according to sex and lipoprotein(a) level. Methods: This prespecified analysis compared the effects of alirocumab versus placebo on lipopro- teins, MACE (coronary heart disease death, non-fatal myocardial infarction, fatal/non-fatal ischemic stroke, unstable angina requiring hospitalization), death, total cardiovascular events, and adverse events in 4762 women and 14,162 men followed for a median of 2.8 years. In post-hoc analysis, we evaluated total cardiovascular events according to sex, baseline lipoprotein(a), and treatment. Results: Women were older, had higher baseline LDL-C levels (89.6 vs 85.3 mg/dL) and lipopro- tein(a) (28.0 vs 19.3 mg/dL) and had more co-morbidities than men. At 4 months, alirocumab lowered LDL-C by 49.4 mg/dL in women and 54.0 mg/dL in men and lipoprotein(a) by 9.7 and 8.1 mg/dL, respectively (both p < 0.0001). Alirocumab reduced MACE, death, and total cardiovascular events sim- ilarly in both sexes. In the placebo group, lipoprotein(a) was a risk factor for total cardiovascular events in women and men. In both sexes, reduction of total cardiovascular events was greater at higher base- line lipoprotein(a), but this effect was more evident in women than men (pinteraction = 0.08). Medication adherence and adverse event rates were similar in both sexes. Conclusions: Alirocumab improves cardiovascular outcomes after ACS irrespective of sex. Reduc- tion of total cardiovascular events was greater at higher baseline lipoprotein(a). ©2024 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) | en_US |
dc.language.iso | En | |
dc.publisher | Elservier | en |
dc.subject | Cardiovascular Diseases | en_US |
dc.subject | Cardiovascular Diseases-blood | |
dc.subject | Cardiovascular Diseases-prevention & control | |
dc.subject | alirocumab | |
dc.subject | Lipoprotein | |
dc.subject | Randomized Controlled Trial | |
dc.title | Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study | en_US |
dc.type | Article | en |
Appears in Collections: | Journal/Magazine Articles |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.